Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases

被引:0
|
作者
Gurbuz, Ali Sami [1 ]
Gode, Funda [2 ]
Kilic, Fatma [3 ]
Gurbuz, Zeynep Umay [4 ]
Deveer, Ruya [5 ]
机构
[1] Novafertil IVF Ctr, Clin Obstet & Gynecol, Konya, Turkey
[2] Bahcesir Univ, Dept Obstet & Gynecol, Fac Med, Istanbul, Turkey
[3] Necmettin Erbakan Univ, Dept Obstet & Gynecol, Fac Med, Konya, Turkey
[4] Koc Univ, Fac Med, Istanbul, Turkey
[5] Sitki Kocman Univ, Dept Obstet & Gynecol, Fac Med, Mugla, Turkey
关键词
ART; freeze-all; GnRH agonist trigger; hypogonadotropic hypogonadism; OHSS; WOMEN;
D O I
10.4274/tjod.galenos.2020.65031
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian Hyperstimulation syndrome (OHSS) is a rare condition in patients with hypogonadotropic hypogonadism. Two patients with hypogonadotropic hypogonadism are reported, a rare case of severe OHSS and a case of prevented OHSS via gonadotropin-releasing hormone (GnRH) agonist trigger, respectively. The first case was a 31-year-old patient. in vitro fertilization (IVF) treatment was performed three times but the patient never developed OHSS. The first patient was diagnosed as having severe OHSS on the ninth day after the fresh embryo transfer. She stayed 66 days in hospital and 50.5 litres of fluid were aspirated from her abdomen. The second case was a 26-year-old and primary infertile patient. She had never undergone IVF treatment. The GnRH agonist stimulation test was performed before IVF treatment. After the ovarian stimulation, GnRH agonist trigger was given. Thirty-two oocytes were retrieved from the ovaries and OHSS did not occur. Although severe OHSS is rare, it can develop in patients hypogonadotropic hypogonadism. If a GnRH stimulation test is performed before ovarian stimulation, OHSS can be prevented because the test allows agonist triggering instead of hCG in hypogonadotropic hypogonadism.
引用
收藏
页码:314 / 317
页数:4
相关论文
共 50 条
  • [21] Pulsatile gonadotropin-releasing hormone therapy: comparison of efficacy between functional hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism
    Everaere, Hortense
    Simon, Virginie
    Bachelot, Anne
    Leroy, Maxime
    Decanter, Christine
    Dewailly, Didier
    Catteau-Jonard, Sophie
    Robin, Geoffroy
    FERTILITY AND STERILITY, 2025, 123 (02) : 270 - 279
  • [22] Ovarian Hyperstimulation Syndrome Prevention Strategies: Oral Contraceptive Pills-Dual Gonadotropin-Releasing Hormone Agonist Suppression with Step-Down Gonadotropin Protocols
    Damario, Mark A.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2010, 28 (06) : 468 - 474
  • [23] Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation
    Pereira, Nigel
    Kelly, Amelia G.
    Stone, Logan D.
    Witzke, Justine D.
    Lekovich, Jovana P.
    Elias, Rony T.
    Schattman, Glenn L.
    Rosenwaks, Zev
    FERTILITY AND STERILITY, 2017, 108 (03) : 532 - 538
  • [24] Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger?
    Connell, Matthew T.
    Patounakis, George
    Healy, Mae Wu
    DeCherney, Alan H.
    Devine, Kate
    Widra, Eric
    Levy, Michael J.
    Hill, Micah J.
    FERTILITY AND STERILITY, 2016, 106 (03) : 584 - +
  • [25] Is coasting effective for preventing ovarian hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone antagonist during an in vitro fertilization cycle?
    Delvigne, A
    Carlier, C
    Rozenberg, S
    FERTILITY AND STERILITY, 2001, 76 (04) : 844 - 846
  • [26] Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles
    Papanikolaou, EG
    Pozzobon, C
    Kolibianakis, EM
    Camus, M
    Tournaye, H
    Fatemi, HM
    Van Steirteghem, A
    Devroey, P
    FERTILITY AND STERILITY, 2006, 85 (01) : 112 - 120
  • [27] Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
    Poggio, Francesca
    Lambertini, Matteo
    Bighin, Claudia
    Conte, Benedetta
    Blondeaux, Eva
    D'Alonzo, Alessia
    Dellepiane, Chiara
    Buzzatti, Giulia
    Molinelli, Chiara
    Boccardo, Francesco
    Del Mastro, Lucia
    CLINICAL MEDICINE INSIGHTS-REPRODUCTIVE HEALTH, 2019, 13
  • [28] Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
    Shin, Jae Jun
    Choi, Young Min
    Jun, Jong Kwan
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Han, Wonshik
    Im, Seock-Ah
    JOURNAL OF BREAST CANCER, 2020, 23 (03) : 268 - 278
  • [29] Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome
    Scotti, Leopoldina
    Irusta, Griselda
    Abramovich, Dalhia
    Tesone, Marta
    Parborell, Fernanda
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2011, 335 (02) : 116 - 125
  • [30] Fertility Preservation and Ovarian Hyperstimulation Syndrome Management in Cancer Care: A Pathophysiological Perspective on Gonadotropin-Releasing Hormone Agonists and Antagonists
    Bedoschi, Giuliano
    Ingold, Caroline
    Navarro, Paula Andrea
    PATHOPHYSIOLOGY, 2024, 31 (02) : 288 - 297